Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Ashton

Showing results (51-60 of 70) with videos related to

Pageof 7
Sort By:
ACS Applied Materials & Interfaces|September 9, 2017
Computational Study of Low Interlayer Friction in Ti<sub>n+1</sub>C<sub>n</sub> (n = 1, 2, and 3) MXeneDifan Zhang, Michael Ashton, Alireza Ostadhossein, et al.
Antimicrobial Agents and Chemotherapy|November 24, 2005
Pitfalls in estimating piperaquine eliminationJoel Tarning, Niklas Lindegårdh, Anna Annerberg, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|July 10, 2025
Population pharmacokinetic-pharmacodynamic modeling of co-administered N,N-dimethyltryptamine and harmine in healthy subjectsAngela Äbelö, John W Smallridge, Robin von Rotz, et al.
Pharmacogenomics|June 23, 2017
MRP2/ABCC2 C1515Y polymorphism modulates exposure to lumefantrine during artemether-lumefantrine antimalarial therapyKarin Vos, Carlotta Lo Sciuto, Rita Piedade, et al.
The AAPS Journal|September 14, 2011
Bilirubin-a potential marker of drug exposure in atazanavir-based antiretroviral therapyDinko Rekić, Oskar Clewe, Daniel Röshammar, et al.
Arzneimittel-Forschung|July 16, 2011
Mono-, di- and trisubstituted derivatives of eflornithine: synthesis for in vivo delivery of DL-alpha-difluoromethylornithine in plasmaTheunis T Cloete, Carl C Johansson, David D N'Da, et al.
Malaria Journal|February 17, 2016
Population pharmacokinetic properties of artemisinin in healthy male Vietnamese volunteersSofia Birgersson, Pham Van Toi, Nguyen Thanh Truong, et al.
Journal of Pharmacokinetics and Pharmacodynamics|October 4, 2011
Non-linear mixed effects modeling of antiretroviral drug response after administration of lopinavir, atazanavir and efavirenz containing regimens to treatment-naïve HIV-1 infected patientsDaniel Röshammar, Ulrika S H Simonsson, Håkan Ekvall, et al.
Clinical Pharmacokinetics|July 12, 2011
HIV/AIDS patients display lower relative bioavailability of efavirenz than healthy subjectsJackson K Mukonzo, Sarah Nanzigu, Dinko Rekić, et al.
Fundamental & Clinical Pharmacology|May 25, 2007
Artemisinin antimalarials moderately affect cytochrome P450 enzyme activity in healthy subjectsSara Asimus, Doaa Elsherbiny, Trinh N Hai, et al.
Pageof 7

Showing results (51-60 of 70) with videos related to

Sort By:
Pageof 7
ACS Applied Materials & Interfaces|September 9, 2017
Computational Study of Low Interlayer Friction in Ti<sub>n+1</sub>C<sub>n</sub> (n = 1, 2, and 3) MXeneDifan Zhang, Michael Ashton, Alireza Ostadhossein, et al.
Antimicrobial Agents and Chemotherapy|November 24, 2005
Pitfalls in estimating piperaquine eliminationJoel Tarning, Niklas Lindegårdh, Anna Annerberg, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|July 10, 2025
Population pharmacokinetic-pharmacodynamic modeling of co-administered N,N-dimethyltryptamine and harmine in healthy subjectsAngela Äbelö, John W Smallridge, Robin von Rotz, et al.
Pharmacogenomics|June 23, 2017
MRP2/ABCC2 C1515Y polymorphism modulates exposure to lumefantrine during artemether-lumefantrine antimalarial therapyKarin Vos, Carlotta Lo Sciuto, Rita Piedade, et al.
The AAPS Journal|September 14, 2011
Bilirubin-a potential marker of drug exposure in atazanavir-based antiretroviral therapyDinko Rekić, Oskar Clewe, Daniel Röshammar, et al.
Arzneimittel-Forschung|July 16, 2011
Mono-, di- and trisubstituted derivatives of eflornithine: synthesis for in vivo delivery of DL-alpha-difluoromethylornithine in plasmaTheunis T Cloete, Carl C Johansson, David D N'Da, et al.
Malaria Journal|February 17, 2016
Population pharmacokinetic properties of artemisinin in healthy male Vietnamese volunteersSofia Birgersson, Pham Van Toi, Nguyen Thanh Truong, et al.
Journal of Pharmacokinetics and Pharmacodynamics|October 4, 2011
Non-linear mixed effects modeling of antiretroviral drug response after administration of lopinavir, atazanavir and efavirenz containing regimens to treatment-naïve HIV-1 infected patientsDaniel Röshammar, Ulrika S H Simonsson, Håkan Ekvall, et al.
Clinical Pharmacokinetics|July 12, 2011
HIV/AIDS patients display lower relative bioavailability of efavirenz than healthy subjectsJackson K Mukonzo, Sarah Nanzigu, Dinko Rekić, et al.
Fundamental & Clinical Pharmacology|May 25, 2007
Artemisinin antimalarials moderately affect cytochrome P450 enzyme activity in healthy subjectsSara Asimus, Doaa Elsherbiny, Trinh N Hai, et al.
Pageof 7